Table 2.
Descriptive statistics of biologic and biosimilar prescribing by biologic drug, aggregated at PA level, 2009–2015.
| Drug (Class) |
Specialization | Statistic | Biosimilar Share (Prescriptions) | Biosimilar Share (DDD 2) | Share of Patients Using Biosimilars in Practice | Number of Patients Using Biosimilars in Practice | Prescriptions Biologics | Prescription Biosimilars | Prescriptions per 1000 Patients, Biologics |
Prescriptions per 1000 Patients, Biosimilars |
|---|---|---|---|---|---|---|---|---|---|---|
| ESAs 1 | GP | mean | 20.64% | 20.49% | 0.31% | 2.53 | 10.9 | 2.99 | 429 | 111 |
| (s.d.) | (6.51%) | (6.38%) | (0.33%) | (2.4) | (10.1) | (2.95) | (419) | (97.3) | ||
| Specialist | mean | 34.73% | 31.92% | 3.37% | 23.8 | 66.3 | 28.4 | 2801 | 947 | |
| (s.d.) | (9.24%) | (8.7%) | (1.14%) | (6.43) | (11.1) | (7.22) | (547) | (273) | ||
| Filgrastim | GP | mean | 61.85% | 61.85% | 0.33% | 4.36 | 7.37 | 5.35 | 28.7 | 20.1 |
| (s.d.) | (15.86%) | (15.97%) | (0.27%) | (3.03) | (3.34) | (3.35) | (15.6) | (14.4) | ||
| Specialist | mean | 75.94% | 75.93% | 1.29% | 7.5 | 11.4 | 9.06 | 110 | 79.6 | |
| (s.d.) | (6.82%) | (6.78%) | (0.63%) | (2.11) | (2.67) | (2.59) | (55.7) | (43.8) | ||
| Somatropin | GP | mean | 3.20% | 3.14% | 0.04% | 0.33 | 6.27 | 0.34 | 409 | 26.5 |
| (s.d.) | (3.99%) | (3.99%) | (0.08%) | (0.42) | (2.5) | (0.42) | (659) | (56.7) | ||
| Specialist | mean | 9.51% | 10.33% | 0.64% | 2.46 | 23.5 | 2.51 | 4456 | 626 | |
| (s.d.) | (4.45%) | (5.12%) | (0.37%) | (1.23) | (7.05) | (1.25) | (2695) | (424) |
1 Erythropoesis-stimulating agents; 2 defined daily dose; 3 general practitioner.